CWC
ALXN

Carolinas Wealth Consulting’s Alexion Pharmaceuticals ALXN Stock Holding History

Carolinas Wealth Consulting’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6
Closed -$1K – 1020
2021
Q2 		$1K Sell
6
-622
-99% -$107K ﹤0.01% 936
2021
Q1 		$96K Hold
628
– – 0.02% 262
2020
Q4 		$98K Hold
628
– – 0.03% 239
2020
Q3 		$72K Buy
628
+149
+31% +$16.1K 0.02% 231
2020
Q2 		$54K Buy
+479
New +$50.9K 0.02% 196

Other funds holding ALXN

Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TD Ameritrade Investment Management
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Carolinas Wealth Consulting's ALXN Position: Q3 2021 in Review

Carolinas Wealth Consulting sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6 shares — an estimated $1K sold.

Carolinas Wealth Consulting first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $98K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Carolinas Wealth Consulting reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 6 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1K.
  • Carolinas Wealth Consulting first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Carolinas Wealth Consulting's Alexion Pharmaceuticals position peaked at $98K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Carolinas Wealth Consulting's 13F filing for Q3 2021, filed 15 Nov 2021.